EUVIMEDEUVIMED entdecken
Crossref

Rationale and Design of the Dapagliflozin Effect on Cardiovascular Events in Acute Heart Failure (DAPA ACT HF)-TIMI 68 Trial

David D Berg, Siddharth M Patel, Paul M Haller, Jan Bělohlávek, Akshay S Desai, Jarosław Drożdż, Silvio E Inzucchi, John J V McMurray, Béla Merkely, Eileen O'Meara, Subodh Verma, Abby L Cange und 3 weitere

JACC: Heart Failure · 2025-05 · 13 (5) · 829-839

DOI: 10.1016/j.jchf.2025.03.014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JACC: Heart Failure, 2025-05. Verfasst von David D Berg und 14 weiteren Autor:innen. Beteiligte Einrichtung: TIMI Study Group, Brigham and Women's Hospital, Boston, Massachusetts, USA; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvar…. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Glucosides, Heart Failure, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although sodium-glucose cotransporter 2 inhibitors reduce the risk of cardiovascular death or worsening heart failure (HF) in patients with chronic HF, there are limited data on initiation in hospitalized patients with HF. DAPA ACT HF-TIMI 68 (Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure - Thrombolysis in Myocardial Infarction 68) is an international, randomized, double-blind trial evaluating the initiation of dapagliflozin (10 mg daily) vs placebo in 2,401 patients hospitalized for acute HF. Patients were enrolled irrespective of left ventricular ejection fraction, type 2 diabetes status, or chronicity of HF (de novo and worsening chronic HF). Randomized participants receive blinded treatment for 2 months. The primary efficacy endpoint is time to first occurrence of cardiovascular death or worsening HF (worsening HF during the index admission, rehospitalization for worsening HF, or urgent HF visit). Key safety endpoints include symptomatic hypotension and worsening kidney function. This is the first cardiovascular outcomes trial designed specifically to evaluate the efficacy and safety of in-hospital initiation of dapagliflozin in patients hospitalized for the management of acute HF. (Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure - Thrombolysis in Myocardial Infarction 68 [DAPA ACT HF-TIMI 68]; NCT04363697; EudraCT # 2022-001262-35).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsGlucosidesHeart FailureSodium-Glucose Transporter 2 InhibitorsAgedFemaleHumansMaleMiddle AgedAcute DiseaseDiabetes Mellitus, Type 2Double-Blind MethodHospitalizationRandomized Controlled Trials as TopicStroke VolumeTreatment OutcomeMulticenter Studies as Topic

Stichwörter der Autor:innen

clinical trialhospitalizationsodium-glucose cotransporter 2 inhibitorsworsening heart failure

Substanzen

Benzhydryl CompoundsdapagliflozinGlucosidesSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • TIMI Study Group, Brigham and Women's Hospital, Boston, Massachusetts, USA; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Electronic address: dber…
  • TIMI Study Group, Brigham and Women's Hospital, Boston, Massachusetts, USA; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • TIMI Study Group, Brigham and Women's Hospital, Boston, Massachusetts, USA; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Department of Cardiology…
  • Second Department of Internal Medicine, Cardiovascular Medicine, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic; Institute for Heart Diseases, Wroclaw Medical Unive…
  • Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Cardiology, Medical University of Lodz, Lodz, Poland.

Zitieren

APA

Berg, D. D., Patel, S. M., Haller, P. M., Bělohlávek, J., Desai, A. S., Drożdż, J., Inzucchi, S. E., McMurray, J. J. V., Merkely, B., O'Meara, E., Verma, S., Cange, A. L., Murphy, S. A., Sabatine, M. S., & Wiviott, S. D. (2025). Rationale and Design of the Dapagliflozin Effect on Cardiovascular Events in Acute Heart Failure (DAPA ACT HF)-TIMI 68 Trial. JACC: Heart Failure, 13(5), 829-839. https://doi.org/10.1016/j.jchf.2025.03.014

Vancouver

Berg DD, Patel SM, Haller PM, Bělohlávek J, Desai AS, Drożdż J, et al. Rationale and Design of the Dapagliflozin Effect on Cardiovascular Events in Acute Heart Failure (DAPA ACT HF)-TIMI 68 Trial. JACC: Heart Failure. 2025;13(5):829-839. doi:10.1016/j.jchf.2025.03.014

BibTeX
@article{Berg2025,
  author = {Berg, David D and Patel, Siddharth M and Haller, Paul M and Bělohlávek, Jan and Desai, Akshay S and Drożdż, Jarosław and Inzucchi, Silvio E and McMurray, John J V and Merkely, Béla and O'Meara, Eileen and Verma, Subodh and Cange, Abby L and Murphy, Sabina A and Sabatine, Marc S and Wiviott, Stephen D},
  title = {Rationale and Design of the Dapagliflozin Effect on Cardiovascular Events in Acute Heart Failure (DAPA ACT HF)-TIMI 68 Trial},
  journal = {JACC: Heart Failure},
  year = {2025},
  volume = {13},
  number = {5},
  pages = {829--839},
  doi = {10.1016/j.jchf.2025.03.014}
}
Kostenlos starten →